Ponesimod vs tamuzimod
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: S1P receptor · full Ulcerative Colitis pipeline
Ponesimod
Marketed by Vanda Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2029 · NCT07686081 (registry estimate)
No aligned efficacy figure on record for this race.
tamuzimod
Developed by Eli Lilly and partners
NCT05156125 · Phase 2 · terminated
This was a randomized, quadruple-blind, placebo-controlled trial in 213 patients using clinical remission on the modified Mayo score, a validated disease-activity measure combining symptoms and endoscopy, as the primary endpoint. Both the 60 mg and 30 mg tamuzimod doses achieved significantly higher remission rates than placebo at week 13.
Reported efficacy
Clinical Remission at 13 Weeks (Day 1 of Induction treatment period to Week 13): Clinical Remission at 13 Weeks (Day 1 of Induction treatment period to Week 13): VTX002 60 mg Once Daily 19/68 (27.9%) | VTX002 30 mg Once Daily 17/71 (23.9%) vs Placebo Once Daily 8/70 (11.4%) (met)
Result source: NCT05156125
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ponesimod | tamuzimod |
|---|---|---|
| Clinical remission (induction) | —Trial running · NCT07686081 | 27.9% vs 11.4%+16.5 vs placeboNCT051561251 other result
|
| Clinical remission (maintenance) | —Trial running · NCT07686081 | —Not reported |
| Clinical response (induction) | —Trial running · NCT07686081 | —Not reported |
| Endoscopic improvement (induction) | —Trial running · NCT07686081 | —Not reported |
| Corticosteroid-free remission (maintenance) | —Trial running · NCT07686081 | —Not reported |
Clinical remission (induction)
- Ponesimod
- —Trial running · NCT07686081
- tamuzimod
- 27.9% vs 11.4%+16.5 vs placeboNCT05156125
1 other result
- 23.9% vs 11.4% NCT05156125
Clinical remission (maintenance)
- Ponesimod
- —Trial running · NCT07686081
- tamuzimod
- —Not reported
Clinical response (induction)
- Ponesimod
- —Trial running · NCT07686081
- tamuzimod
- —Not reported
Endoscopic improvement (induction)
- Ponesimod
- —Trial running · NCT07686081
- tamuzimod
- —Not reported
Corticosteroid-free remission (maintenance)
- Ponesimod
- —Trial running · NCT07686081
- tamuzimod
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Ponesimod: no structured comparison results are available for Ulcerative Colitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Ponesimod: 0 of 4 rows · tamuzimod: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | tamuzimod |
|---|---|
| Dropout rate | 4.3%60 mg once dailya NCT05156125 · Phase 2 · monotherapy show 6 more results—60 mg once daily NCT05156125 · Phase 2 · monotherapy —60 mg once daily NCT05156125 · Phase 2 · monotherapy —60 mg once daily NCT05156125 · Phase 2 · monotherapy 4.1%30 mg once daily NCT05156125 · Phase 2 · monotherapy —30 mg once daily NCT05156125 · Phase 2 · monotherapy —30 mg once daily NCT05156125 · Phase 2 · monotherapy |
| Discontinued due to AEs | 2.9%60 mg once dailya NCT05156125 · Phase 2 · monotherapy show 6 more results—60 mg once daily NCT05156125 · Phase 2 · monotherapy —60 mg once daily NCT05156125 · Phase 2 · monotherapy —60 mg once daily NCT05156125 · Phase 2 · monotherapy 1.4%30 mg once daily NCT05156125 · Phase 2 · monotherapy —30 mg once daily NCT05156125 · Phase 2 · monotherapy —30 mg once daily NCT05156125 · Phase 2 · monotherapy |
| Serious AEs | —60 mg once dailya NCT05156125 · Phase 2 · monotherapy show 6 more results4.3%60 mg once daily NCT05156125 · Phase 2 · monotherapy 0%60 mg once daily NCT05156125 · Phase 2 · monotherapy 4.2%60 mg once daily NCT05156125 · Phase 2 · monotherapy —30 mg once daily NCT05156125 · Phase 2 · monotherapy 2.7%30 mg once daily NCT05156125 · Phase 2 · monotherapy 5.4%30 mg once daily NCT05156125 · Phase 2 · monotherapy |
| Most frequent reported AEs | 60 mg once dailya upper respiratory tract infection 8.6% (placebo 1.4%) headache 5.7% (placebo 2.9%) anaemia 2.9% (placebo 8.6%) NCT05156125 · Phase 2 · monotherapy show 4 more results60 mg once daily alanine aminotransferase increased 6.1% (placebo 1.4%) aspartate animotransferase increased 6.1% (placebo 0%) gamma-glutamyltransferase increased 6.1% (placebo 1.4%) NCT05156125 · Phase 2 · monotherapy 60 mg once daily lymphopenia 28.9% (placebo 0%) nasopharyngitis 7.4% (placebo 4.3%) upper respiratory tract infection 6.3% (placebo 1.4%) NCT05156125 · Phase 2 · monotherapy 30 mg once daily headache 6.8% (placebo 2.9%) anaemia 5.5% (placebo 8.6%) lymphopenia 1.4% (placebo 0%) NCT05156125 · Phase 2 · monotherapy 30 mg once daily gamma-glutamyltransferase increased 10.8% (placebo 1.4%) alanine aminotransferase increased 5.4% (placebo 1.4%) arthralgia 5.4% (placebo 0%) NCT05156125 · Phase 2 · monotherapy |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
tamuzimod
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ponesimod's landscape · tamuzimod's landscape